Detalles de la búsqueda
1.
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.
Mult Scler
; 28(5): 842-846, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34882037
2.
Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
Mult Scler
; 26(1): 48-56, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30785358
3.
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
Mult Scler
; 26(14): 1866-1876, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31762387
4.
The sequential natalizumab - alemtuzumab therapy in patients with relapsing forms of multiple sclerosis (SUPPRESS) trial - Part I: Rationale and objectives.
J Cent Nerv Syst Dis
; 14: 11795735221123911, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36062026
5.
CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis.
Neurodegener Dis Manag
; 11(2): 99-111, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33517769
6.
Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years.
Mult Scler Relat Disord
; 49: 102717, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33476880
7.
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial.
Ther Adv Neurol Disord
; 14: 1756286420982134, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34035833
8.
Effect of Multiple Sclerosis on Daily Activities, Emotional Well-being, and Relationships: The Global vsMS Survey.
Int J MS Care
; 22(4): 158-164, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32863783
9.
Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223.
J Neurol
; 267(11): 3343-3353, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32583052
10.
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study.
CNS Drugs
; 34(9): 973-988, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32710396
11.
Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings.
Front Neurol
; 10: 253, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30967831
Resultados
1 -
11
de 11
1
Próxima >
>>